by Raynovich Rod | Mar 19, 2023 | 2024-25 Life Science Portfolios, Macro
Update-2 3/24..12;15p ..Biopharma and healthcare stocks rally. Update over weekend. ABBV AMGN BIIB GILD REGN VRTX and UNH and Medtech ISRG MDT…small caps EVH PACB. Update-1 3/22…Away from FEDspeak”. We believe that sm aller cap life science stocks...
by Raynovich Rod | Mar 12, 2023 | 2024-25 Life Science Portfolios, Macro
Small Cap Biotechs Slammed by SVB Collapse Small Cap biotechs have been hit hard and needs time to sort out. Momentum and sentiment in a risk-off mode. Opportunity to assess good stocks for longer term after seeing how they trade. Nothing like a banking crisis to...
by Raynovich Rod | Mar 6, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-2 3/9/23… Silicon Valley Bank Collapse triggers more selling in small cap biotechs.Sold XBI at $79 for 4% profit now at $75. Large cap biopharma holding up well in green. Jobs grew solidly but at a slower pace.So looking for a 25 bps rate increase. Risk...
by Raynovich Rod | Feb 26, 2023 | 2024-25 Life Science Portfolios
Update-2 3/2 Better tape action today. Big winners: CRSP, CYRX, NTLA, NVTA, QDEL, PACB,SUPN. Review on Weekend. Cowen conference next week March 8 should help life science sector. Update-1 2/28 Risk Off when FED rules with rates rising. Equities fighting higher...
by Raynovich Rod | Feb 20, 2023 | 2024-25 Life Science Portfolios
SMID Life Science Stocks: Investor or Trader? Despite choppy trading there is an upward tilt to life science stocks since 9/26/22 lows. Three stocks are strong holds: EVH,HOLX and QDEL. Can gene therapy break through in 2023? Our SMID (small and mid) life science...
by Raynovich Rod | Feb 5, 2023 | 2024-25 Life Science Portfolios
Update-2 2/17…QDEL beats on earnings and revenue of $3.37B. EPS of $13.80.Business combination with Ortho still in flux. Stock looks good on technical basis with accumulation. Good value with P/S 1.97, PE is 5.42 and P/FCF 6.45. Recommendation is a...
by Raynovich Rod | Jan 30, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-4 Mixed stock market in healthcare and biotech but in an overall weak day as FED and CPI looms. IBB down 0.62% to $132 level. Abbvie (ABBV) beats with Revenue of $58.04B an increase of 3.3% but Humira biosimilars weigh on profit forecast ; pipeline and Botox...
by Raynovich Rod | Jan 23, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-2… 1/31… Good value in Pfizer (PFE) as stock near new lows with PE of 8.26 stock at $43.50. but nobody cares as boom times for COVID vaccines end.Provides Full-Year 2023 Revenue Guidance(4) of $67.0 to $71.0 Billion and Adjusted Diluted EPS(3)...
by Raynovich Rod | Jan 22, 2023 | 2024-25 Life Science Portfolios, Clinical Diagnostics and Tools
Update-1…1/29/23 Risk On! Speculative small cap life science stocks continue to run with the XBI up 2.76% for the week. Movers for the week included: CRSP up 6.39%, CYRX up 6.07%, GERN up 4.7%, and VCYT up 4.58%. Some of the winners in our portfolio were losers...
by Raynovich Rod | Jan 17, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Rally During #JPM23 Favors Smaller Caps Bolt-On acquisitions expected to bolster product pipelines. Macro headwinds lessened with moderating inflation. Small and mid-cap biotechs provide an innovation narrative. Here are some takeaways from #JPM23:...
